This company develops microbiome-based therapeutics to improve infant gut health and prevent conditions like necrotizing enterocolitis. Their drugs, currently undergoing clinical trials, aim to support healthy immune system function in infants, particularly preterm babies.
Funding
$55M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CMTFounders
Product
Problem
Infants, especially preterm babies, often lack a fully developed gut microbiome, which can lead to immune deficiencies and serious conditions such as necrotizing enterocolitis (NEC). Conventional nutrition does not consistently provide the specific bacterial strains needed to optimally utilize human milk oligosaccharides (HMOs) that support microbiome development.
Solution
Infinant Health produces probiotic formulations that are intended to be taken together with breast milk, delivering targeted Bifidobacterium infantis strains that efficiently metabolize HMOs. Their flagship strain, B. infantis EVC001, and the next‑generation drug strain INF108 are H5‑positive, showing superior growth on lacto‑N‑tetraose and lacto‑N‑neotetraose compared with H5‑negative strains. By colonizing the infant gut early, these probiotics aim to enhance immune maturation, reduce the risk of NEC in premature infants, and promote long‑term health outcomes. The products are designed for use during the narrow developmental window when the infant microbiome is most receptive to beneficial colonization.
Target Audience
Primary customers are healthcare professionals and neonatal care providers who prescribe microbiome‑supporting probiotics for term and preterm infants, as well as parents seeking clinically validated probiotic supplements to use with breast milk.
Features
- H5‑positive B. infantis strains with proven high‑efficiency utilization of key human milk oligosaccharides
- Formulated for co‑administration with breast milk to maximize colonization and metabolic activity
- INF108 drug‑grade strain specifically developed for NEC prevention in preterm infants
- Demonstrated fitness advantage over H5‑negative strains, supporting stable gut colonization
- Scalable probiotic delivery platform compatible with standard infant feeding practices